| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $23.7M | — |
| R&D Expense | $241.6M | +48.2% |
| SG&A Expense | $120.9M | +80.6% |
| Operating Income | -$339.7M | -47.7% |
| Net Income | -$318.8M | -52.3% |
| EPS (Basic) | -$3.72 | -24.8% |
| EPS (Diluted) | -$3.72 | -24.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $154.1M | -47.8% |
| Short-term Investments | $418.8M | +52.1% |
| Accounts Receivable | $7.6M | — |
| Inventory | $366K | — |
| Current Assets | $603.1M | +3.8% |
| Total Assets | $724.8M | +18.3% |
| Current Liabilities | $103.5M | +78.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$274.9M | -71.2% |
| Investing Cash Flow | -$219.8M | -286.9% |
| Financing Cash Flow | $353.4M | +33.8% |
| Total Liabilities |
| $436.7M |
| +644.1% |
| Stockholders' Equity | $288.1M | -48.0% |